The AstraZeneca (LON:AZN) share price is soaring. Here’s what I’d do

The AstraZeneca (LON:AZN) share price has stormed ahead of GlaxoSmithKline in 2022. Do Q1 results justify that outperformance?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A senior woman sits up on the exam table at a doctors appointment. She is dressed casually in a blue sweater and has a smile on her face as she glances at the doctor. Her female doctor is wearing a white lab coat and seated in front of her as she takes notes on a tablet.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price soared in 2021 and this year. It’s now up 40% over the past 12 months, and up nearly 130% in five years. Some of that will surely be down to having its name attached to one of the most successful Covid-19 vaccines.

AstraZeneca has been working to reinvigorate its drug development pipeline and resume sustainable earnings growth. It’s not there yet, but a first quarter update gives us a glimpse of what’s on the horizon.

Astra expects a high teens percentage increase in revenue in 2022. And that should generate a mid-to-high twenties percentage rise in core EPS.

That’s impressive, especially after a 32% gain in core EPS in 2021. We saw a major difference between core and reported EPS for the year, with the latter coming in much lower.

The company put that down to the acquisition of Alexion, and various impairments and restructuring charges.

AstraZeneca share price valuation

On a core EPS basis, the current AstraZeneca share price suggests a trailing P/E of 25. Should the company’s guidance prove accurate, that would fall to 19 for 2022. And that looks a lot more respectable than any super-high P/E based on reported EPS.

It makes comparisons with GlaxoSmithKline more meaningful too. AstraZeneca has outstripped GSK over the past 12 months. But their valuations are not wildly far apart.

On 2021 underlying earnings, we’re looking at a trailing P/E of 16 for GlaxoSmithKline. There is clearly still a premium built in to the AZN share price though, possibly due to the coronavirus factor.

AstraZeneca’s first quarter saw a 20% rise in core EPS, at constant exchange rates. That doesn’t match up to full-year guidance yet, but it’s a good start. And a 60% rise in total revenue in the quarter bodes well for the rest of the year.

Oncology vs vaccines

Key development milestones during the quarter came from various cancer drug developments. Oncology revenue overall rose 25%, and that segment is the biggest contributor to total revenue.

Right now, I think the AstraZeneca share price might be a bit overvalued, based on Covid vaccine sentiment. But Astra’s vaccines and immune therapies (V&I) segment is well down the list in terms of size. In Q1, V&I revenue was only half that generated by oncology treatments.

I really do see the pharmaceuticals sector as a long-term cash generator. Due to the nature of the drug development cycle, it can take years and huge investment for new discoveries to come through. But that should be no problem for a long-term investor with a horizon of a decade, or more.

Buy on the dips?

I do expect to see AstraZeneca coming through the lean times, with a few drugs likely to hit blockbuster status in the coming years.

I just think the share price is too high right now, especially compared with GlaxoSmithKline’s valuation. Glaxo has been paying out around twice the dividend yield too.

So, for now, it’s a no for me. But I might buy on future dips.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »